113. 筋ジストロフィー Muscular dystrophy Clinical trials / Disease details


臨床試験数 : 646 薬物数 : 471 - (DrugBank : 105) / 標的遺伝子数 : 59 - 標的パスウェイ数 : 170

  
4 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04386304
(ClinicalTrials.gov)
July 13, 20201/5/2020Safety and Biomarker Response to (+)-Epicatechin in Becker Muscular DystrophyA Phase 1, Open-label, Dose Escalation Study to Evaluate the Safety and Preliminary Efficacy of Orally Administered (+)-Epicatechin in Patients With Becker or Becker-like Muscular Dystrophy With Continued Ambulation Past 16 Years of AgeBecker Muscular DystrophyDrug: (+)-EpicatechinEpirium Bio Inc.NULLCompleted16 Years59 YearsMale22Phase 1United States
2NCT02964377
(ClinicalTrials.gov)
November 20167/11/2016Plus Epicatechin Duchenne Muscular Dystrophy in Non-ambulatory AdolescentsA Single Center Dose Ranging Pilot Study of (+)-Epicatechin in Non-ambulatory Adolescents With Duchenne Muscular Dystrophy and Pre-symptomatic Cardiac DysfunctionDuchenne Muscular DystrophyDrug: (+)- EpicatechinCraig McDonald, MDCardero Therapeutics, Inc.Completed8 Years17 YearsMale15Phase 1/Phase 2United States
3NCT03236662
(ClinicalTrials.gov)
November 20167/11/2016(-)- Epicatechin Becker Muscular DystrophyUCD0115B: An Open-label Extension Study of Purified Epicatechin to Improve Mitochondrial Function, Strength and Skeletal Muscle Exercise Response in Becker Muscular DystrophyBecker Muscular DystrophyDrug: (-)-EpicatechinCraig McDonald, MDCardero Therapeutics, Inc.Completed18 Years70 YearsMale2Phase 2United States
4NCT01856868
(ClinicalTrials.gov)
May 20139/5/2013Use of (-)-Epicatechin in the Treatment of Becker Muscular Dystrophy (Pilot Study)An Open-label Pilot Study of Purified Tea-derived Epicatechin to Improve Mitochondrial Function, Strength and Skeletal Muscle Exercise Response in Becker Muscular Dystrophy.Becker Muscular DystrophyDrug: (-)-epicatechinCraig McDonald, MDCardero Therapeutics, Inc.Completed18 Years60 YearsMale7Phase 1/Phase 2United States